市场调查报告书
商品编码
1470903
癌症药物市场:按适应症、药物类别、给药途径、分销和最终用途 - 2024-2030 年全球预测Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年癌症治疗市场规模为1,757.8亿美元,2024年达1,884.1亿美元,预计2030年将达2,944.2亿美元,复合年增长率为7.64%。
癌症药物是用于治疗、诊断和预防癌症的特殊药物。这些药物透过各种作用机制靶向癌细胞,因此在恶性的治疗中至关重要。癌症治疗药物分为多种类型,包括化疗、标靶治疗、免疫疗法、荷尔蒙疗法等,每种药物在癌症治疗中都扮演着独特的角色。全球癌症发生率的快速上升,加上抗癌药物开发的投资和政府资助的增加,正在推动市场成长。然而,新药的开发、测试和获得核准的成本对製造商构成了重大挑战。此外,基因组定序技术和生物技术的进步,以及对个人化药物的需求不断增加,正在为市场成长创造利润丰厚的机会。
主要市场统计 | |
---|---|
基准年[2023] | 1757.8亿美元 |
预测年份 [2024] | 1884.1亿美元 |
预测年份 [2030] | 2944.2亿美元 |
复合年增长率(%) | 7.64% |
由于药物类别的高精度和较少的副作用,标靶治疗变得越来越重要
化疗涉及使用细胞毒性药物来杀死癌细胞或阻止它们生长。化疗是最古老的癌症治疗方法之一,用于治疗多种类型的癌症。对于晚期癌症或已扩散的癌症,化疗通常是首选。化疗可以单独使用,也可以与其他治疗方法合併使用。荷尔蒙疗法透过阻止身体产生荷尔蒙的能力并阻止其作用来减缓或阻止荷尔蒙敏感肿瘤的生长。这种疗法主要用于乳癌和摄护腺癌,这些癌症通常会随着荷尔蒙的反应而生长。免疫疗法增强人体对抗癌症的自然防御能力。免疫疗法使用体内或实验室製造的物质来增强和恢復免疫系统功能。对于具有表明可能对这种治疗有反应的标记的癌症,例如黑色素瘤、肺癌和肾癌,免疫疗法是首选。标靶治疗针对有助于癌症生长和存活的特定基因、蛋白质或组织环境。这种治疗方法可以阻止癌细胞生长和扩散,同时限制对健康细胞的伤害。标靶治疗特别适用于具有这些药物可以针对的基因突变的癌症,例如某些类型的肺癌、乳癌和大肠癌。
最终用途癌症诊所的扩张加速了对癌症药物的需求
家庭医疗保健对癌症药物的需求显着增加。患者及其家人通常会发现居家医疗更加舒适,并减少了经常去医院带来的心理压力。医院是癌症药物管理的重要终点,尤其是需要先进基础设施和密切医疗监测的治疗。该医院治疗多种癌症,并且经常治疗需要住院治疗的严重病例。癌症诊所位于居家医疗和医院之间,在门诊环境中提供专门护理。这些诊所对于癌症患者的持续治疗和监测至关重要,并且通常可以轻鬆获得最新药物和临床试验。
区域洞察
受高医疗保健支出、强大的研发基础设施和大型製药公司的强大影响力,美洲地区是癌症药物的主要市场。新型药物输送系统和标靶治疗的专利凸显了该国的创新,而对癌症研究和倡议的大量投资则强调了我们对根除癌症的承诺。欧洲市场的特点是统一的监管环境,为癌症药物的开发和核准创造了有利的环境。该市场因成员国之间的价格敏感性而有所不同,需要创新的治疗方法以及具有成本效益的癌症治疗解决方案。中东和非洲地区呈现出多元化的市场环境,波湾合作理事会(GCC)国家对创新癌症治疗表现出较高的购买力,而撒哈拉以南非洲国家则强调可近性和可负担性。在中阶不断壮大、医疗保健支出不断增加以及政府旨在改革医疗保健的倡议的推动下,亚太地区的癌症药物市场正在迅速扩张。亚太地区国家在癌症研究和开发中发挥关键作用,在国内和全球癌症市场上取得了长足的进展。
FPNV定位矩阵
FPNV定位矩阵对于评估癌症药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对癌症治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.癌症治疗药物市场的市场规模与预测为何?
2.在癌症药物市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.癌症药物市场的技术趋势和法规结构是什么?
4.癌症治疗药物市场主要厂商的市场占有率为何?
5.进入抗癌药物市场的合适型态和策略手段是什么?
[194 Pages Report] The Oncology Drugs Market size was estimated at USD 175.78 billion in 2023 and expected to reach USD 188.41 billion in 2024, at a CAGR 7.64% to reach USD 294.42 billion by 2030.
Oncology drugs are specialized pharmaceutical agents used in the treatment, diagnosis, and prevention of cancer. These drugs are pivotal in the management of malignancies as they target cancer cells with various mechanisms of action. Oncology drugs can be categorized into several types, including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others, each playing a unique role in oncology care. The surging prevalence of cancer worldwide, coupled with the increase in investments and government funding in the development of cancer drugs, propel the market growth. However, the cost of developing, testing, and securing regulatory approval for new drugs poses a significant challenge to the manufacturers. Furthermore, advancements in genomic sequencing technologies and biotechnology, along with the growing need for personalized medicines, create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 175.78 billion |
Estimated Year [2024] | USD 188.41 billion |
Forecast Year [2030] | USD 294.42 billion |
CAGR (%) | 7.64% |
Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
Chemotherapy involves the utilization of cytotoxic drugs to kill or hamper the growth of cancer cells. It is among the oldest forms of cancer treatment and can be used across various cancer types. Chemotherapy is often preferred for advanced cancers or cancers that have metastasized. It can be used as a sole treatment & in combination with other therapies. Hormonal therapy slows or prevents the growth of hormone-sensitive tumors by stopping the body's ability to produce hormones & by interfering with hormone action. This therapy is primarily used for breast and prostate cancers, which often grow in response to hormones. Immunotherapy boosts the body's natural defenses to combat cancer. It utilizes substances made by the body or in a laboratory to enhance and restore immune system function. Immunotherapy is preferred for cancers that have markers indicating they may respond to this treatment, such as melanoma, lung cancer, and kidney cancer. Targeted therapy targets the specific genes, proteins, or the tissue environment contributing to cancer growth and survival. This type of therapy stops the growth and prevalence of cancer cells while limiting damage to healthy cells. Targeted therapy is specifically used for cancers with genetic mutations that can be targeted with these drugs, such as certain types of lung, breast, and colorectal cancers.
End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
Home healthcare has seen a significant uptick in the demand for oncology drugs, attributed largely to the increasing preference for at-home treatments. Patients and families often find home healthcare options more comfortable, reducing the psychological stress associated with frequent hospital visits. Hospitals remain a critical endpoint for the administration of oncology drugs, especially for treatments that require advanced infrastructure and close medical supervision. They cater to a wide spectrum of cancers, often dealing with more severe cases that necessitate in-patient care. Specialty cancer clinics offer a middle ground between home healthcare and hospitals, providing specialized care in an outpatient setting. These clinics are pivotal for the ongoing treatment and monitoring of cancer patients, often facilitating access to the latest drugs and clinical trials.
Regional Insights
The American region represents a major market for oncology drugs, driven by high healthcare expenditure, robust research and development infrastructure, and a strong presence of leading pharmaceutical companies. Patents in novel drug delivery systems and targeted therapies highlight the country's innovation, while significant investment in cancer research & initiatives underscores a commitment to combating cancer. The European market is marked by a harmonized regulatory landscape that fosters a conducive environment for oncology drug development and approval. Differentiated by price sensitivity across member states, the market demands cost-effective oncology solutions alongside innovative therapies. The Middle East & Africa region presents a diverse market landscape, with Gulf Cooperation Council (GCC) countries showing high purchasing power for innovative oncology treatments, contrasted with Sub-Saharan Africa's focus on accessibility and affordability. The APAC region's oncology drugs market is rapidly expanding, fueled by a growing middle class, increased healthcare spending, and government initiatives aimed at healthcare reform. The APAC countries with significant players in oncology research and development are making strides in both the domestic and global oncology markets.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Oncology Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncology Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Oncology Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncology Drugs Market?
3. What are the technology trends and regulatory frameworks in the Oncology Drugs Market?
4. What is the market share of the leading vendors in the Oncology Drugs Market?
5. Which modes and strategic moves are suitable for entering the Oncology Drugs Market?